Garuda - Garba Rujukan Digital

Article Per Year (5 Year)

All

Indonesian Journal of Cancer

ijoc
Website

Published by National Cancer Center-Dharmais Cancer Hospital

ISSN : 19783744 EISSN : 23556811 DOI : https://www.doi.org/ 10.33371

Core Subject : Health, Science,

Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Public Health

Indonesian Journal of Cancer is a peer-reviewed and open-access journal. This journal is published quarterly (in March, June, September, and December) by Dharmais Cancer Hospital - National Cancer Center. Submissions are reviewed under a broad scope of topics relevant to experimental and clinical cancer research. Articles are original research that needs to be disseminated and written in English. All submitted manuscripts will go through the double-blind peer review and editorial review before being granted acceptance for publication. The journal publishes original research articles, case reports, and review articles under the following categories: cancer management, cancer prevention, cancer etiology, epidemiology, molecular oncology, cancer diagnosis and therapy, tumor pathology, surgical oncology, medical oncology, radiation oncology, interventional radiology, as well as early detection.

Arjuna Subject : Kedokteran - Onkologi

Articles 562 Documents

30 31 32 33 34

pTNM System in Non Small Cell Lung Carcinoma Heriawaty Hidajat; Sutjahjo Endarjo; Ruth E Sembiring; Aziza Icksan; Elisna Syahrudin; Agung Wibawanto
Indonesian Journal of Cancer Vol 2, No 4 (2008): Oct - Dec 2008
Publisher : National Cancer Center - Dharmais Cancer Hospital

Prognosis karsinoma paru berhubungan dengan berbagai macam faktor, antara lain : usia, jenis kelamin, ukuran tumor, staging, jenis sel dan derajat diferensiasi, invasi kepembuluh darah, dinding dada, efusi pleura, adanya jaringan ikat, keterlibatan KGB, reaksi radang, ploidy DNA dan ekspresi onkogen.Adanya hubungan langsung antara staging klinik dan angka ketahanan hidup sudah dibuktikan, terutama untuk karsinoma bukan sel kecil. Staging TNM merupakan parameter prognostik terpenting dan merancang terapi pada karsinoma paru, seperti pada kebanyakan tumor lainnya.Semua kasus karsinoma paru sebaiknya ditangani oleh tim kanker paru multidisiplin. Jika ditemukan perbedaan bermakna diantara temuan klinik dan radiologik, sebaiknya diagnosis sediaan patologik jaringan paru di review ulang, jika memungkinkan oleh ahli patologi kedua yang berpengalaman dalam kanker paru.Prosedur pemeriksaan imunohistokimia harus dilakukan bila diagnosis histopatologik tidak pasti.Kata Kunci: pTNM, NSCLC, kanker paru-paru

Telaah Awal Pemetaan Indikasi Pemeriksaan 18F-FDG PET/CT di RS Kanker "Dharmais" dengan Pedoman Appropriateness Criteria dari IAEA KARDINAH KARDINAH; SARININGSIH HIKMAWATI; ROSALINA HASAN; BUDI DARMAWAN
Indonesian Journal of Cancer Vol 6, No 4 (2012): Oct - Dec 2012
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v6i4.284

Pemanfaatan pemeriksaan dengan biaya mahal memerlukan health technology assessment (HTA) sehingga memberikan dampak yang optimal bagi tata laksana pengobatan pasien selanjutnya. Pedoman dari International Atomic Energy Agency (IAEA) yang diterapkan dalam pelaksanaan pemeriksaan 18F-FDG PET/CT scan bertujuan sebagai telaah awal pemetaan indikasi sehingga dapat dilakukan perbaikan dan pengembangan di masa mendatang.Dilakukan evaluasi retrospektif terhadap 116 pasien yang melakukan pemeriksaan pada Mei sampai Agustus 2012 di RS Kanker Dharmais. Indikasi pemeriksaan dikelompokkan sesuai dengan rekomendasi IAEA, yaitu diagnosis, penentuan stadium, evaluasi respons terapi, dan evaluasi rekurensi.Hasilnya menunjukkan persentase pemeriksaan 18F-FDG PET/CT scan dengan indikasi evaluasi respons terapi sebesar 48,2%, pada limfoma maligna 12,9% dan kanker payudara 8,6%. Sedangkan evaluasi adanya rekurensi sebesar 37,9%, masing-masing pada kanker payudara 15,5% dan limfoma maligna 4,3%. Indikasi penentuan stadium adalah 9,4% dan diagnosis 4,3%.Kesimpulannya, pemeriksaan 18F-FDG PET/CT/CT merupakan modalitas yang penting dalam evaluasi terapi dan rekurensi pada pasien kanker bila diterapkan sesuai dengan indikasi yang jelas. Dengan demikian, perubahan tata laksana yang berguna untuk keberhasilan pengobatan pasien dapat tercapai.Kata kunci: 18F-F PET/CT, indikasi pemeriksaan, evaluasi respons terapi, evaluasi rekurensi.

Mutasi EGFR pada Non-Small Cell Lung Cancer di Rumah Sakit Kanker “Dharmais” LENNY SARI; PURWANTO PURWANTO
Indonesian Journal of Cancer Vol 10, No 4 (2016): October - December 2016
Publisher : National Cancer Center - Dharmais Cancer Hospital

ABSTRACTThis descriptive study illustrated the proportion of EGFR mutation in non-small cell lung cancer (NSCLC) at “Dharmais” National Cancer Hospital. Examination of EGFR mutation started in 2015, 196 data was collected and 68 data being analyses. Fixed Formalin Paraffin Embedded (FFPE) processed by cobas® 4800 real time polymerase chain reaction. The results shown 34% patients NSCLC with EGFR mutation and all of them was single mutation. EGFR mutation happens in Exon 21 L858R 10 cases (44 %), Exon 19del 12 cases (52 %) and the type of Exon 20 S768I 1 case (4 %). This study found a high proportion of EGFR mutation.ABSTRAKStudi deskriptif ini menggambarkan proporsi mutasi Epidermal Growth Factor Receptor (EGFR) pada pasien dengan kanker paru di Rumah Sakit Kanker “Dharmais”. Telah terkumpul 196 data, tetapi terdapat 68 data yang telah selesai dilakukan pemeriksaan mutasi EGFR. Mutasi EGFR diperiksa menggunakan Formalin-Fixed Paraffin-Embedded (FFPE) dengan teknologi cobas® 4800 real-time polymerase chain reaction. Ditemukan 34% pasien dengan mutasi EGFR. Pada kelompok tersebut hanya ditemukan single mutation. Mutasi EGFR terjadi pada Exon 21 L858R sebanyak 10 kasus (44%), Exon 19del 12 kasus (52%), dan tipe Exon 20 S768I sebanyak 1 kasus (4%). Studi ini masih berlangsung dan diharapkan dapat memberikan gambaran yang lebih komprehensif tentang mutasi EGFR pada kanker paru.

The Relationship of Perioperative Blood Transfusion With Bladder Cancer Mortality In Radical Cystectomy Patients Aria Utama Nur Qohari; Ahmad Zulfan Hendri
Indonesian Journal of Cancer Vol 14, No 3 (2020): September
Publisher : National Cancer Center - Dharmais Cancer Hospital

Background: Perioperative blood transfusion is correlated to adverse effects which lead to mortality on a few cases of patients with malignancy, especially kidney tumors. The objective of this study is to evaluate the relationship between blood transfusion timings and survival of patients with bladder cancer who undergo radical cystectomy and measure the differences in the outcomes between patients undergoing intraoperative blood transfusion and patients undergoing blood transfusion after surgery.Methods: This research is a retrospective analytic study with a cohort design. Thirty patients with bladder tumors who performed radical cystectomy and did not undergo perioperativechemotherapy were included in the study data. Recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) were analyzed by the Kaplan-Meier method and compared between groups with log-rank tests. Chi-square test was used for comparative evaluation of each group. Univariate and multivariate analyzes were performed to evaluate the relationship between clinical and pathological variables with risks such as RFS, CSS, and OS. P<.005 were considered statistically significant, and SPSS software was used for the entire analysis process.Results: From a total of 29 patients who had a radical cystectomy, 22 patients received perioperative blood transfusion. The 17 patients had the transfusion intraoperatively while the rest had the transfusion after the operation. The mean of blood loss was 1491 cc and the mean of survival was 13.2 months. Intraoperative blood transfusion was associated with a significantly increased risk of disease recurrence (HR: 1.32; P=.034), bladder cancer mortality (HR: 1.65; P=.015), and all-cause mortality (HR: 12.38; P=.013).Conclusions: Intraoperative blood transfusion is significantly associated with an increased risk of cancer mortality. Further investigation is needed to determine the biological mechanismsunderlying patient outcomes.

The Need of Chest Computer Tomography in The Assessment of Mediastinal Seminoma and Non Seminomatous Germ Cell Tumors Aziza Icksan; Reny Luhur; Elisna -; Heriawati -
Indonesian Journal of Cancer Vol 1, No 4 (2007): Oct - Dec 2007
Publisher : National Cancer Center - Dharmais Cancer Hospital

Germ cell tumor mediastinum merupakan salah satu dari masa mediastinum anterior yang terdiri dari teratoma, seminoma dan non seminomatous. Diferential diagnosa dari germ cell tumor pada mediastinum anterior meliputi massa thymus, massa tiroid dan lymphoma. Dalam membuat diagnosa, disamping gejala klinis dan usia pasien, pemeriksaan seromarker serta temuan foto toraks dan CT toraks sangat membantu. Diagnosa pasti ditegakkan berdasarkan pemeriksaan sitologi dan histopatologi dari spesimen yang berperan penting sebagai baku emas.Penentuan lokasi tumor yang tepat sangatlah penting dalam penanganan pasien. Foto toraks merupakan pemeriksaan imaging awal yang dilakukan pada pasien yang sudah diketahui atau dicurigai menderita germ cell tumor mediastinum. Pemeriksaan Chest CT dengan kontras merupakan prosedur rutin dalam penanganan germ cell tumor mediastinum.Kasus non seminomatous dan seminoma germ cell tumor pada mediastinum anterior dilaporkan pada laki laki berusia 17 dan 15 tahun. Pada kedua pasien ini telah dilakukan pemeriksaan foto toraks dan CT toraks dengan menggunakan kontras media.Kata kunci : germ cell tumor mediastinum, seminoma, non seminomatous, foto toraks, CT toraks. ABSTRACTV'**Mediastinal germ cell tumor is one of the anterior mediastinal mass which consists of teratoma, seminoma and non seminomatous. The differential diagnosis of the anterior mediastinal germ cell tumor such as thymic mass, thyroid mass and lymphoma. The diagnosis depends on some criteria such as, clinical finding, the age of the patient, sero markers, location of the mass and findings on the chest radiograph and chest CT. Cytology and histopathology finding from the specimens are paramount important as a gold standard.Accurate assessment of the location is very important to manage the patient. Chest radiograph is usually the first imaging study obtained in a patient with known or suspected of mediastinal germ cell tumor, and for further evaluation enhanced Chest CT nowadays has become the routine procedure in assessing mediastinal germ cell tumor.Cases of the mediastinal non seminomatous and seminoma germ cell tumors were reported in a 17 and 15 year old males. Chest radiograph and enhanced chest CT were used to diagnosing and assessing of the patients.Key word : mediastinal germ cell tumor, seminoma, non seminomatous, chest radiograph , Enhanced chest CT.

Terapi Hormonal Primer pada Penderita Kanker Prostat: Evaluasi Survival dan Faktor Prediksinya Johan -; Chaidir Arif Mochtar; Rainy Umbas
Indonesian Journal of Cancer Vol 5, No 3 (2011): Jul - Sep 2011
Publisher : National Cancer Center - Dharmais Cancer Hospital

Tujuan: Mengevaluasi efektivitas terapi hormonal secaraorchidectomydan medikamentosa sebagai pengobatan primer pada penderita kanker prostat dan faktor prediksi terhadapsurvivalkedua modalitas pengobatan tersebut.Materi dan metode: Kami mengumpulkan seluruh data penderita kanker prostat yang mendapatkan terapi hormonal primer, baik berupaorchidectomybilateral maupun medikamentosa di RSCM dan RSKD periode Januari 1995Desember 2008.Follow upterakhir sampai Juni 2010. Data pra-terapi seperti usia,stagingklinik, volume prostat, PSA,gradingtumor dari WHO, serta metastasis tulang dianalisis sebagai faktor prediksi 5 tahunsurvival.Hasil: dalam periode empat belas tahun terdapat 693 penderita kanker prostat di RSCM dan RSKD. Sebanyak 465 di antaranya mendapatkan terapi hormonal primer, yang selanjutnya dibagi 2 kelompok, yaitu kelompokorchidectomydan medikamentosa yang berjumlah masing-masing 251 dan 214 penderita. Angkasurvivallima tahun secara keseluruhan adalah 51%, sedangkan pada kelompokorchidectomydan medikamentosa masing-masing adalah 53,6% dan 48,7% (p=0,481). Faktor prediksisurvival5 tahun tidak ada yang bermakna pada kelompokorchidectomy, sedangkan pada kelompok medikamentosa PSA<20 dangradingtumor ? 2 memiliki angkasurvival5 tahun lebih baik secara bermakna.Kesimpulan: angkasurvivallima tahun pada kelompokorchidectomydan hormonal medikamentosa secara statistik tidak ada perbedaan yang bermakna. Pada kelompokorchidectomy, tidak ada parameter yang berhubungan secara bermakna dengan 5 tahunsurvival, sedangkan pada kelompok hormonal medikamentosa PSA saat diagnosis <20 ng/mL ataugradingtumor ? 2 akan mempunyaisurvival5 tahun lebih baik.Katakunci:orchidectomy, hormonal medikamentosa,survivallima tahun, PSA, tumorgrading.

Complete Pathological Response in Stage IV Rectal Carcinoma: Proper Planning and Place is a Key Deep Lamichhane; Suraj Suwal; Resham Rana; Shweta Baral; Rishikesh Narayan Shrestha
Indonesian Journal of Cancer Vol 16, No 2 (2022): June
Publisher : National Cancer Center - Dharmais Cancer Hospital

Introduction: Liver metastasis is frequently encountered in patients with rectal cancer; it can be synchronous or metachronous. Some selected patients can be treated with curative intent using multimodality therapy under the care of a dedicated team in a comprehensive cancer center. However, the treatment is long and tiring for the treating team, the patient, and the relatives. Treatment is difficult to execute in a country like ours with a limited number of cancer centers. We present a patient from a remote village with stage IV disease, who completed all modalities of treatment with a favorable outcome. Case Presentation: A fifty-five-year-old man from a remote village presented to us with a complaint of per rectal bleeding. He was diagnosed with rectal carcinoma with solitary liver metastases. He received multimodality treatment in the form of chemotherapy, radiotherapy, and surgery. He attained a complete pathological response at both primary and metastatic sites.Conclusions: Good outcomes can be achieved in selected stage IV rectal cancer. This requires multimodality treatment and a proper plan, preferably in a comprehensive cancer center

Uji Validitas pada Program Skrining Payudara di RS Onkologi, Surabaya Sri Redjeki; Anggraheny -; Lies Mardiyana
Indonesian Journal of Cancer Vol 3, No 4 (2009): Oct - Dec 2009
Publisher : National Cancer Center - Dharmais Cancer Hospital

Strategi paling efektif dalam menanggulangi kanker payudara adalah pencegahan sekunder, yaitu upaya deteksi dini dan pengobatan segera. Penemuan mammografi adalah terobosan terbesar dalam sejarah penanganan kanker payudara. Pemeriksaan mammografi dapat menemukan kanker payudara sebelum timbul keluhan atau disebut dengan stadium praklinis.Sejak 1995, RS Onkologi melakukan kegiatan skrining payudara jenis opportunity screening atau lebih dikenal dengan istilah case finding. Di sini skrining mammografi dilakukan terhadap masyarakat yang datang tanpa keluhan dan atas kesadaran sendiri melakukan deteksi. Tulisan ini melaporkan kegiatan skrining payudara sejak Januari 2008 hingga Desember 2008. Dari 22.813 kasus yang datang di RSOS, 4.125 di antaranya adalah kasus baru. Kegiatan skrining tersebut menemukan 357 kasus kanker payudara dan hanya 8 kasus (0,9%) yang masih stadium 0 (tidak teraba). Dari 1.388 kasus skrining payudara, dilakukan 9 lokalisasi prosedur dan ditemukan 8 kasus kanker payudara T0 (0,57%). Kemudian dilakukan analisis ilmiah mengenai pengalaman menangani lesi payudara yang tak teraba di RSOS.Kata kunci: skrining payudara, lesi tak teraba, lokalisasi prosedur

Koagulasi Intravaskuler Diseminata pada Kanker ANDREE KURNIAWAN; NATA PRATAMA HARDJO LUGITO
Indonesian Journal of Cancer Vol 9, No 3 (2015): Jul - Sept 2015
Publisher : National Cancer Center - Dharmais Cancer Hospital

Disseminated Intravascular Coagulation is one of thrombosis manifestation other than venous thromboembolism, which onset is acute and has slight different clinical manifestation that tends to be chronic. Pathogenesis of the DIC in hematology malignancy is caused by the activation of fibrinolytic pathway by tumor cells. In solid tumor the pathogenesis is mainly because of the activation of cogulation factor by tissue factor expressed by tumor cells. Thediagnosis of DIC in cancer still needs further validation from the international society of thrombosis and hemostasisand Japanese society hematology criteria in cancer subjects. The principle of therapy for DIC in cancer patients is management of the cancer itself as the underlying etiology with the target is remission. The uses of anticoagulant therapy needs further clinical trial in the future. Coagulation factor and platelet transfusion can be given if there is significant bleeding.Koagulasi intravaskuler diseminata (KID) adalah manifestasi trombosis lain selain tromboemboli vena yang bersifat akut. Pada pasien kanker gambarannya sedikit berbeda, yaitu cenderung bersifat kronik, tergantung pada jenis kankernya. Patogenesis KID pada keganasan hematologi adalah akibat fibrinolisis yang meningkat. Sedangkan pada tumor solid terjadi akibat aktivasi faktor koagulasi oleh faktor jaringan yang diekspresikan oleh sel kanker. Diagnosis KID pada kanker masih memerlukan validasi kriteria dari perhimpunan trombosis hemostasis internasional dan Jepang pada kelompok pasien kanker. Prinsip terapi KID pada kanker adalah tata laksana kanker yang menjadi penyebab, dengan target remisi penyakit. Pemberian antikoagulan memerlukan uji klinis menggunakan populasi pasien kanker. Transfusi faktor koagulasi dan atau trombosit hanya diberikan apabila terdapat perdarahan yang bermakna.

Sarcopenia in Cancer Patients Andree Kurniawan
Indonesian Journal of Cancer Vol 13, No 3 (2019): September
Publisher : National Cancer Center - Dharmais Cancer Hospital

Introduction: Sarcopenia in cancer patients, especially in advanced stage, recently known as an emerging problem. Firstly, sarcopenia is found in elderly patients. The diagnosis of sarcopenia needs evaluation of muscle composition and function and physical activity. Sarcopenia will give negative impacts such as increased mortality, chemo-toxicity, and decreased quality of life. Here, we review the current evidence describing the definition, impact, risk factors, mechanisms, diagnosis and treatment of sarcopenia in cancer patients.Method: We identified 48 studies and/or review articles evaluating sarcopenia in cancer patients by searching PubMed and EMBASE databases. Results: Sarcopenia is reported across all stages and types of cancers. There is a new definition of sarcopenia that is reported in 2019 paper. The risk factors or causes of sarcopenia in cancer are complex depending on the clinical settings of each patient. SARC-F questionnaire can be used to screen cancer patients in clinical settings. The diagnostic evaluation and cut-off measurement of sarcopenia especially in cancer varied across studies. The loss of muscle mass that happens during chemotherapy will make a poor prognosis. Sarcopenia can worsen chemotherapy toxicity. Combination exercise with adequate dietary supplementation, adequate energy, and protein are important in the management of sarcopenia in cancer patients.Conclusions: Patients with cancer belong to a population at risk of developing sarcopenia before and after chemotherapy. Sarcopenia diagnosis needs the evaluation of muscle mass and muscle strength or physical performance. Physical activity exercise is the best strategy to reduce sarcopenia in cancer patients.

Page 32 of 57 | Total Record : 562

30 31 32 33 34

Filter by Year

2007 2025

Filter By Issues

All Issue Vol 19, No 3 (2025): September Vol 19, No 2 (2025): June Vol 19, No 1 (2025): March Vol 18, No 4 (2024): December Vol 18, No 3 (2024): September Vol 18, No 2 (2024): June Vol 18, No 1 (2024): March Vol 17, No 4 (2023): December Vol 17, No 3 (2023): September Vol 17, No 2 (2023): June Vol 17, No 1 (2023): March Vol 16, No 4 (2022): December Vol 16, No 3 (2022): September Vol 16, No 2 (2022): June Vol 16, No 1 (2022): March Vol 15, No 4 (2021): December Vol 15, No 3 (2021): September Vol 15, No 2 (2021): June Vol 15, No 1 (2021): March Vol 14, No 4 (2020): December Vol 14, No 3 (2020): September Vol 14, No 2 (2020): June Vol 14, No 1 (2020): March Vol 13, No 4 (2019): December Vol 13, No 3 (2019): September Vol 13, No 2 (2019): June Vol 13, No 1 (2019): March Vol 12, No 4 (2018): October-December Vol 12, No 3 (2018): July-September Vol 12, No 2 (2018): April-June Vol 12, No 1 (2018): Jan - Mar Vol 11, No 4 (2017): October- December 2017 Vol 11, No 3 (2017): July - September 2017 Vol 11, No 2 (2017): April - June Vol 11, No 1 (2017): Jan-Mar Vol 10, No 4 (2016): October - December 2016 Vol 10, No 3 (2016): July - September 2016 Vol 10, No 2 (2016): April - June 2016 Vol 10, No 1 (2016): Jan - Mar 2016 Vol 9, No 4 (2015): Okt - Des 2015 Vol 9, No 3 (2015): Jul - Sept 2015 Vol 9, No 2 (2015): April-Juni 2015 Vol 9, No 1 (2015): Jan - Mar 2015 Vol 8, No 4 (2014): Oct - Dec 2014 Vol 8, No 3 (2014): Jul - Sep 2014 Vol 8, No 2 (2014): April-Juni 2014 Vol 8, No 1 (2014): Jan - Mar 2014 Vol 7, No 4 (2013): Oct - Dec 2013 Vol 7, No 3 (2013): Jul - Sep 2013 Vol 7, No 2 (2013): Apr - Jun 2013 Vol 7, No 1 (2013): Jan - Mar 2013 Vol 6, No 4 (2012): Oct - Dec 2012 Vol 6, No 3 (2012): Jul - Sep 2012 Vol 6, No 2 (2012): Apr - Jun 2012 Vol 6, No 1 (2012): Jan - Mar 2012 Vol 5, No 4 (2011): Oct - Dec 2011 Vol 5, No 3 (2011): Jul - Sep 2011 Vol 5, No 2 (2011): Apr - Jun 2011 Vol 5, No 1 (2011): Jan - Mar 2011 Vol 4, No 4 (2010): Oct - Dec 2010 Vol 4, No 3 (2010): Jul - Sep 2010 Vol 4, No 2 (2010): Apr - Jun 2010 Vol 4, No 1 (2010): Jan - Mar 2010 Vol 3, No 4 (2009): Oct - Dec 2009 Vol 3, No 3 (2009): Jul - Sep 2009 Vol 3, No 2 (2009): Apr - Jun 2009 Vol 3, No 1 (2009): Jan - Mar 2009 Vol 2, No 4 (2008): Oct - Dec 2008 Vol 2, No 3 (2008): Jul - Sep 2008 Vol 2, No 2 (2008): Apr - Jun 2008 Vol 2, No 1 (2008): Jan - Mar 2008 Vol 1, No 4 (2007): Oct - Dec 2007 Vol 1, No 3 (2007): Jul - Sep 2007 Vol 1, No 2 (2007): Apr - Jun 2007 Vol 1, No 1 (2007): Jan - Mar 2007 More Issue

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name
Bayu Brahma

Contact Email
journal.cancer@gmail.com

Phone
+628176389956

Journal Mail Official
admin@indonesianjournalofcancer.or.id

Editorial Address
National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta

Location
Kota adm. jakarta barat,

Dki jakarta

INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name Bayu Brahma

Contact Email journal.cancer@gmail.com

Phone +628176389956

Journal Mail Official admin@indonesianjournalofcancer.or.id

Editorial Address National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta

Location Kota adm. jakarta barat, Dki jakarta INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Contact Name
Bayu Brahma

Contact Email
journal.cancer@gmail.com

Phone
+628176389956

Journal Mail Official
admin@indonesianjournalofcancer.or.id

Editorial Address
National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta

Location
Kota adm. jakarta barat,

Dki jakarta

INDONESIA